Month: September 2026

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Jeneen Slack, CFP®, CDFA®, founder and partner of Northstar Financial Advisors, LLC, has joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. Slack reported serving more than $270 million in client assets* and joins LPL from Raymond James.

With nearly 20 years of industry experience, Slack built her practice on a belief that financial advice is most impactful when it is rooted in strong personal relationships. Initially inspired by a desire to help women feel more confident discussing and managing their finances, her approach today is centered on helping individuals and families make informed decisions about their financial futures.

Based in Danville, Calif., Slack serves a diverse clientele throughout the Bay Area, including professionals, families, retirees and individuals navigating major life transitions. As a Certified Divorce Financial Analyst (CDFA®), she specializes in helping clients understand the financial implications of divorce and supporting their long-term planning needs beyond the process itself.

“Relationships are truly at the heart of everything we do at Northstar,” Slack said. “We’ve intentionally built a personalized service model where every member of our team knows our clients personally and understands what matters most to them. Whether we’re helping someone navigate retirement, prepare a child for financial independence or make complex decisions during a divorce, our goal is to provide guidance that evolves alongside our clients’ lives.”

Slack, along with her business partner and fellow financial advisor Eric Slack, is supported by Kari Jeha, Jon Lee and V. John Threlkeld. Together, they bring decades of combined industry experience and a hands-on approach focused on delivering individualized service. Beyond working with clients, the practice is deeply committed to community engagement – regularly hosting educational workshops, retirement planning programs and client events designed to foster deeper connections and financial literacy.

Why Northstar Financial Advisors Chose LPL

As she looked ahead to the next chapter of her career, Slack sought a partner that would give her the flexibility to build Northstar around her vision for the future while providing the scale and resources of a leading financial services firm. She was particularly attracted to LPL’s commitment to innovation, its advanced technology capabilities and the depth of support available to established advisors.

“I’m at a point in my career where I wanted a partner that is continually investing in the future of advice,” Slack said. “LPL gives us the flexibility and resources to operate the way we believe is best for our clients, while providing the technology and support to help our team work more efficiently. That combination allows us to focus on what matters most — delivering thoughtful, personalized guidance and maintaining the strong relationships we’ve built with our clients.”

Marc Cohen, Chief Growth Officer at LPL Financial, said, “What Jeneen has built at Northstar is personal by design. She and her team take the time to know their clients, helping women engage more confidently with their finances and guiding individuals and families through the decisions and transitions that shape their lives. We are honored that Jeneen chose LPL for Northstar’s next chapter and look forward to helping the team extend that experience to more clients.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Northstar Financial Advisors and LPL Financial are separate entities.

LPL Financial does not offer tax advice or tax preparation services.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1171024

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder (“MDD“). The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.

The Phase 2 clinical trial is authorized to proceed by Health Canada and will enroll up to 200 participants across multiple sites in Canada, evaluating the safety and efficacy of a single supervised dose of natural psilocybin in the treatment of MDD. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline, the most widely used clinician-rated measure of depressive symptom severity in trials of this kind.

“A 200-subject Phase 2 trial in major depressive disorder is the largest clinical commitment Optimi has made to date. We will supply our own naturally derived psilocybin, manufactured at our GMP facility, and we will have exclusive ownership of the trial results,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “As we broaden our strategy to include clinical drug development, this Phase 2 trial is an initial step toward potential registration. Few companies in this sector are commercial today while also advancing their own clinical development. In Canada, we already hold a Drug Establishment Licence and supply psilocybin through Health Canada’s Special Access Program. This trial builds directly on that foundation, and we can comfortably fund it with current cash on hand.”

The clinical trial is set to be one of the largest clinical studies of naturally derived psilocybin to date, and will include periodic interim safety and efficacy readouts, with full topline results available after dosing and follow-up evaluations are completed for all 200 participants.

MDD is among the most common mental health conditions worldwide, affecting an estimated 332 million people, according to the World Health Organization.¹ A substantial proportion of patients do not respond adequately to existing antidepressant treatments, which typically require weeks of continuous use before clinical benefits emerge.

¹World Health Organization, Depressive disorder (depression) fact sheet, 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/depression

The safety and efficacy of psilocybin assisted therapy to treat MDD is still under investigation and none of Optimi’s psilocybin drug products received market authorization by Health Canada.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol monitoring solution with the Lake County Community Corrections Program in Indiana. Lake County is Indiana’s second-most populous county, serving residents in the greater Chicago metropolitan region.

The BreathLogix system will support court-ordered alcohol monitoring initiatives administered by Lake County’s community corrections program staff. The deployment is designed to assist program administrators in monitoring participant compliance with court-imposed abstinence requirements while improving operational efficiency and reducing administrative burden.

Under the program, participants are required to undergo scheduled or random alcohol testing as a condition of probation, treatment, pre-trial release, or other court-supervised programs. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller.

Under the program, participants may be required to undergo scheduled or random alcohol testing as a condition of probation, diversion, treatment, pre-trial release, or other court-supervised programs. BreathLogix enables participants to provide breath samples autonomously while maintaining identity verification through integrated photo capture technology.

BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver real-time alerts via SMS and email to designated program administrators when positive results are detected.

The deployment further expands Cannabix’s presence within the U.S. corrections, probation, treatment, and public safety markets where organizations are seeking automated alcohol testing solutions that improve compliance oversight while reducing staffing requirements.

Figure 1. BreathLogix Alcohol device available with for County Sobriety Programs

BreathLogix supports a broad range of alcohol monitoring applications, including:

• Court-ordered alcohol monitoring
• Probation and parole programs
• Pre-trial release supervision
• Diversion and specialty court programs
• Treatment and recovery programs
• Random and scheduled alcohol testing
• Workplace and safety-sensitive screening
• Return-to-work and fitness-for-duty assessments

By enabling frequent, reliable and automated alcohol screening, BreathLogix helps courts, treatment providers and supervision agencies strengthen compliance monitoring, improve participant accountability and enhance public safety outcomes.

Marketing Agreement

The Company has entered into a marketing services agreement (the “Agreement”) with Outside the Box Capital Inc. (“OTBC”), an arm’s-length marketing firm based in Oakville, Ontario. Pursuant to the Agreement, OTBC will provide marketing services, including social media marketing, content planning and creation, and the production and distribution of feature content regarding the Company through OTBC’s proprietary media channels and selected third-party platforms. The Agreement is effective September 9, 2026, for a term of six months. In consideration for the services to be provided under the Agreement, the Company has agreed to pay OTBC a one-time cash fee of $150,000 plus applicable taxes and 335,000 stock options (the “Options”) to acquire common shares of the Company at an exercise price of $0.45 per share for a period of one year from the date of grant. The Options will vest in accordance with the policies of the Canadian Securities Exchange and the Company’s equity incentive plan. Any common shares issued upon the exercise of the Options will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws.

OTBC is controlled by Jason Coles. OTBC and Mr. Coles are arm’s-length parties to the Company. Other than the Options described above, neither OTBC nor Mr. Coles currently holds any direct or indirect interest in the Company or its securities. OTBC has no relationship with the Company other than pursuant to the Agreement described in this news release.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, performance and adoption of the Company’s BreathLogix alcohol monitoring system; the expected use of the system by community corrections agencies and other public sector organizations; the Company’s ability to expand deployments of BreathLogix in the United States and other jurisdictions; the commercialization and market acceptance of the Company’s products and technologies; the Company’s ability to enter into additional customer, distribution, service, or strategic partnership agreements; and the Company’s ongoing business, product development and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully deploy and support its technologies; customer adoption and retention; regulatory developments; changes in government procurement practices or community corrections requirements; competitive developments; technological advancements by competitors; economic and market conditions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve commercial acceptance, that existing deployments will lead to additional contracts or revenue opportunities, or that any anticipated business objectives, strategic initiatives, partnerships, or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c280215e-c351-42df-b85c-5f581f46994e

 

Bank of Åland Plc
Stock exchange release
September 10, 2026, 15.45 EEST

Bank of Åland Plc to increase prime rate

The Bank of Åland Plc (Ålandsbanken Abp) has decided to increase its prime rate by 0.25 percentage points, from 2.25 per cent to 2.50 per cent. The basis for this decision is rising market interest rates. The change goes into effect on September 24, 2026.

Bank of Åland Plc

For further information, please contact:
Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505